GDRX logo

GDRX
GoodRx Holdings Inc

5,918
Mkt Cap
$867.01M
Volume
855,427.00
52W High
$5.81
52W Low
$1.77
PE Ratio
43.76
GDRX Fundamentals
Price
$2.65
Prev Close
$2.56
Open
$2.60
50D MA
$2.31
Beta
1.35
Avg. Volume
1.27M
EPS (Annual)
$0.0853
P/B
1.39
Rev/Employee
$1.14M
$1,248.38
Loading...
Loading...
News
all
press releases
Hims & Hers Deepens Personalized Care Through Platform Expansion
HIMS broadens beyond telehealth, adding labs, new hormone programs and global expansion as it builds a personalized care platform.
News Placeholder
More News
News Placeholder
OptimizeRx Cuts Revenue Outlook: Will Pressures Ease Ahead?
OPRX cuts 2026 revenue view to $95-$100M as MFN pricing disruption and macro uncertainty squeeze budgets - will pressures ease?
News Placeholder
Should You Add OPRX Stock to Your Portfolio Pre-Q1 Earnings?
OptimizeRx nears Q1 earnings amid declining revenue forecasts, softer trends and a cautious outlook, raising questions on near-term upside.
News Placeholder
GoodRx (GDRX) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for GoodRx (GDRX) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
News Placeholder
GoodRx Holdings, Inc. (GDRX) Q1 Earnings Match Estimates
GoodRx (GDRX) delivered earnings and revenue surprises of -5.41% and +7.73%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
News Placeholder
GoodRx Reports First Quarter 2026 Results
GoodRx Holdings, Inc. (Nasdaq: GDRX) ('we,' 'us,' 'our,' GoodRx, or the Company), the leading platform for medication savings in the U.S., has released its financial results for the first quarter of...
News Placeholder
GoodRx Holdings, Inc. (NASDAQ:GDRX) Receives Average Recommendation of "Hold" from Brokerages
Shares of GoodRx Holdings, Inc. (NASDAQ:GDRX - Get Free Report) have earned a consensus recommendation of "Hold" from the fifteen analysts that are presently covering the firm, MarketBeat Ratings reports. Three research analysts have rated the stock with a sell rating, seven have issued a hold rat...
News Placeholder
GoodRx (NASDAQ:GDRX) Trading 8.7% Higher - Should You Buy?
GoodRx (NASDAQ:GDRX) Shares Up 8.7% - What's Next...
News Placeholder
GoodRx Expands Offerings to Now Include Ozempic Pill for Type 2 Diabetes Patients
GoodRx (Nasdaq: GDRX), the leading platform for prescription savings in the U.S., today announced that it is providing access to self-pay pricing for Novo Nordisks Ozempic pill (oral semaglutide...
News Placeholder
Hims & Hers Expands Digital-First Access to Personalized Healthcare
HIMS broadens digital-first care with Novo Nordisk GLP-1 access, new cancer detection and Labs tools, along with expansion into Canada and Europe.
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available